Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
RESEARCH TOOLSreports
Precision BioSciences (DTIL) Stock Price & Analysis
655 Followers
DTIL Stock Chart & Stats
Day’s Range$9.65 - $10.1
52-Week Range― - ―
Previous Close$9.82
Volume21.92K
Average Volume (3M)N/A
Market Cap
$70.75M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 08, 2024EPS Estimate
-$2.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,916,239
10 Day Avg. Volume83,949
30 Day Avg. Volume120,004
Standard Deviation0.33
R-Squared0.06
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)2.71
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.50Price Target Upside296.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Precision BioSciences News
PremiumCompany Announcements
Precision BioSciences Faces Partnership Termination, Eyes Future
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Product DevelopmentPrecision's PBGENE-HBV represents a novel treatment approach with the potential to achieve the clinical goals of a functional cure for CHB, poised to be the first and only potentially curative gene editing program to enter the clinic.
Financial Health And MilestonesPrecision ended the year with a strong cash position, providing a financial runway into the latter half of the decade, ensuring the company is well-equipped to hit multiple milestones in validating their ARCUS genome editing technology.
Innovation And Market PositionWith in vivo data showing up to 45% high-efficiency gene insertion in non-dividing cells of non-human primates, Precision BioSciences is carving out a leading position in the gene editing space, leveraging their ARCUS technology.
Bears Say
Clinical And Commercialization RisksThe stock faces significant risks associated with clinical development and commercialization, which could impede its progress and affect its market performance.
Collaboration TerminationThe end of the collaboration with Lilly could disrupt the gene editing pipeline and may lead to uncertainties regarding future development and funding.
Competitive MarketDespite promising preclinical data, the company operates in a highly competitive DMD market, which may limit its potential to successfully differentiate its product.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Currently, no data Available
What is Precision BioSciences’s market cap?
Currently, no data Available
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Mar 27, 2024. The company reported -$4.06 earnings per share for the quarter, missing the consensus estimate of -$2.047 by -$2.013.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -$2.43.
How many shares outstanding does Precision BioSciences have?
Currently, no data Available
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$4.06 in its last earnings report, missing expectations of -$2.047. Following the earnings report the stock price went up 1.804%.
Which hedge fund is a major shareholder of Precision BioSciences?
Among the largest hedge funds holding Precision BioSciences’s share is Caxton Associates LP. It holds Precision BioSciences’s shares valued at N/A.
---
Precision BioSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.50 (296.09% Upside)
$38.50 (296.09% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.88%
12-Months-Change
Fundamentals
Return on Equity
-157.63%
Trailing 12-Months
Asset Growth
-32.91%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
---
DTIL Stock 12 Months Forecast
Average Price Target
$38.50
▲(296.09% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Adverum Biotechnologies
―
Editas Medicine
―
Beam Therapeutics
―
Best Analysts Covering DTIL
1 Year
1 Year Success Rate
1/26 ratings generated profit
1 Year Average Return
-52.88%
reiterated a buy rating 9 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 3.85% of your transactions generating a profit, with an average return of -52.88% per trade.
---